DexCom Inc (DXCM)vsLumexa Imaging Holdings, Inc. Common Stock (LMRI)
DXCM
DexCom Inc
$84.11
-0.36%
HEALTHCARE · Cap: $32.21B
LMRI
Lumexa Imaging Holdings, Inc. Common Stock
$10.54
+2.03%
HEALTHCARE · Cap: $1.01B
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 376% more annual revenue ($4.97B vs $1.04B). DXCM leads profitability with a 20.1% profit margin vs -2.7%. DXCM earns a higher WallStSmart Score of 74/100 (B).
DXCM
Strong Buy74
out of 100
Grade: B
LMRI
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+90.0%
Fair Value
$680.73
Current Price
$84.11
$596.62 discount
Intrinsic value data unavailable for LMRI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 38 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Trading at 12.1x book value
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 3.2%
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bull Case : LMRI
The strongest argument for LMRI centers on Price/Book.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Bear Case : LMRI
The primary concerns for LMRI are EPS Growth, Market Cap, Operating Margin. Debt-to-equity of 1.59 is elevated, increasing financial risk.
Key Dynamics to Monitor
DXCM profiles as a mature stock while LMRI is a turnaround play — different risk/reward profiles.
DXCM is growing revenue faster at 13.1% — sustainability is the question.
DXCM generates stronger free cash flow (185M), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
DXCM scores higher overall (74/100 vs 38/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Lumexa Imaging Holdings, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States. The company is headquartered in Raleigh, North Carolina.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?